Involvement of interleukin-1 in the inhibition of in vivo insulin release: possible role of adrenal glands.
The effect of recombinant human interleukin-1 beta (rhIL-1b) on in vivo insulin secretion was examined in intact and adrenalectomized (ADX) rats under conscious and pentobarbital anesthetized conditions. In conscious rats, rhIL-1b dose-dependently decreased blood glucose levels at 2 h in both groups and significantly inhibited insulin release only at doses of 1 and 10 micrograms/kg in ADX rats. Under pentobarbital anesthesia, rhIL-1b administration decreased blood glucose levels 2 h later in both intact and ADX rats and resulted in severe hypoglycemia in ADX rats. At 2 h later, rhIL-1b significantly suppressed insulin release by pentobarbital injection in both intact and ADX rats. It is concluded that rhIL-1b suppresses in vivo insulin secretion in conscious ADX and anesthetized rats.
Shimizu
H
H
First Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan.
Uehara
Y
Y
Shimomura
Y
Y
Negishi
M
M
Kobayashi
I
I
Kobayashi
S
S
D000311:Adrenal Glands / Q000502:physiology*; D000315:Adrenalectomy; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D007328:Insulin / Q000378:metabolism*; D007375:Interleukin-1 / Q000494:pharmacology*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D011994:Recombinant Proteins / Q000494:pharmacology
D001786:Blood Glucose; D007328:Insulin; D007375:Interleukin-1; D011994:Recombinant Proteins